Recombinant Antibodies
Rational Design
Reading Nucleic Acids
Diverse Architectures. Atomic Precision.
Guided by high-resolution structures and computational modeling, we understand how our antibodies function at the atomic level and the molecular logic governing their interactions with DNA and RNA. This allows us to create modification specific binders in a variety of designs best suited for an application.
Rationally Engineered. Biochemically Characterized.
We strive to maintain high standards of purity, reproducibility, and functional activity for our antibodies. This is enabled by the recombinant production of monoclonal antibodies that have been rationally engineered and biochemically characterized for optimal affinity and specificity to their nucleic acid target. Our designs are meticulously tested to determine their molecular fingerprint across a suite of diverse DNA and RNA antigens to enhance performance and minimize cross reactivity.
Cymba Antibody Portfolio
CYM-1901
Target: 8-oxoA
PCT WO/2024/151994
8-oxoA is a major byproduct of oxidative damage to Adenine in DNA, RNA, and free nucleosides such as ATP. We develop monoclonal antibodies with high affinity and specificity for this lesion in multiple contexts such as DNA and RNA oligonucleotides, messenger RNA, and ATP.
CYM-1902
Target: 8-oxoG
In process
8-oxoG is the archetype of oxidative nucleic acid damage and characteristic of aging, mutagenesis, inflammation, and tissue damage. Our structural and biochemical studies enable us to create novel 8-oxoG antibodies with superior lesion sensing in a diverse suite of DNA, RNA, and GTP antigens.
CYM-1903
Target: Undisclosed
In process
